Hypersensitivity reactions to biologicals: An EAACI position paper

Hypersensitivity reactions to biologicals: An EAACI position paper

Biologicals are crucial targeted therapeutic agents in oncological, immunological, and inflammatory diseases, and their use in clinical practice is broadening. In recent years, the spread of Personalized Precision Medicine has facilitated a proliferation of new treatment options, especially biologic...

Full description

Bibliographic Details
Main Authors: Alvarez-Cuesta, E. (Author), Bavbek, S. (Author), Castells, M. (Author), Dursun, A.B (Author), Hamadi, S. (Author), Madrigal-Burgaleta, R. (Author), Pagani, M. (Author), Sanchez-Sanchez, S. (Author), Vultaggio, A. (Author)
Format: Article
Language:English
Published: John Wiley and Sons Inc 2022
Subjects:
abatacept
abdominal pain
adalimumab
anakinra
Article
belimumab
benralizumab
bevacizumab
biological product
bloating
bradycardia
brentuximab vedotin
cetuximab
chest tightness
chill
clinical feature
clinical practice
cytokine release
desensitization
diarrhea
drug contraindication
drug hypersensitivity
dupilumab
dyspnea
efalizumab
etanercept
evidence based practice
faintness
female
fever
golimumab
headache
health care organization
human
hypertension
hypotension
immediate type hypersensitivity
immunoglobulin E
in vitro study
infliximab
infusion related reaction
injection site reaction
interferon
interleukin derivative
male
Medline
mepolizumab
mogamulizumab
nausea
nose obstruction
obinutuzumab
ofatumumab
omalizumab
pain
pembrolizumab
personalized medicine
pertuzumab
presyncope
provocation test
pruritus
reslizumab
risk factor
rituximab
search engine
secukinumab
serum sickness
skin test
systematic review
tachycardia
thorax pain
tocilizumab
tongue swelling
trastuzumab
urticaria
ustekinumab
Web of Science
wheezing
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items